Discovery platform for therapeutics development
Atreca’s proprietary discovery platform generates and develops therapeutics based on rapid characterization of human adaptive immune response at the single cell level. Foundation partners use the platform to isolate novel human monoclonal antibodies, gain immune response and vaccination insights, and generate new tools for global health vaccine discovery and development.
- Focus areas
- Life Sciences
- Investment type
- Direct equity
- Status
- Active
- Initial investment
- Series A
- Partnered in
- 2012
- Headquarters
- USA
More about our work
Our focus
We embrace science and technology innovations that solve old problems in new ways, challenge status quos, and build on past breakthroughs. Our six domains of focus comprise 40+ program strategies across the foundation’s nearly $9B annual charitable support.
Investment Approach
How the Strategic Investment Fund is fostering partnerships with the private sector to leverage the globe’s most groundbreaking global innovations for societal good.
Our Team
The SIF Investment Committee brings depth of experience to global investment programs, with a proven track record of innovation across sectors and scale.